Overview

Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine Versus Capecitabine Monotherapy in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma Who Failed Platinum-containing Treatment

Status:
Not yet recruiting

Trial end date:
2027-09-01

Target enrollment:

Participant gender:

Summary

This is a randomized, open-label, positive-controlled, multicenter Phase Ш study to evaluate the efficacy and safety of mitoxantrone hydrochloride liposome injection combined with capecitabine versus capecitabine monotherapy in patients with recurrent metastatic nasopharyngeal carcinoma.

Phase:

Phase 3

Details

Lead Sponsor:

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Treatments:

Capecitabine
Mitoxantrone